Pengaruh Perbedaan Perbandingan Kosnsentrasi Surfaktan dan Kosurfaktan 45:5, 40:10, 35:15 terhadap Stabilitas Fisik Self- Nanoemulsifying Drug Delivery Systems (Snedds) Atenolol dengan Fase Minyak Zaitun (Olive Oil)
Abstract Views:
676 times
PDF Downloads:
1772 times
Abstract
ABSTRAK-Penelitian ini membahas tentang bagaimana cara meningkatkan kelarutan serta bioavailabilitas atenolol di dalam tubuh dengan memperkecil ukuran partikel atenolol menjadi bentuk nano (SNEDDS). Pada penelitian ini dibuat SNEDDS atenolol dengan tiga formula yang berbeda, masing-masing dengan jumlah bahan aktif (2%) dan minyak (49%) yang sama, namun dengan kosentrasi surfaktan dan kosurfaktan yang berbeda-beda, yaitu formula satu dengan perbandingan 45:5, formula dua dengan perbandingan 40:10, serta formula tiga dengan perbandingan 35:15. Kemudian, ketiga formula tersebut akan dievaluasi karakteristik fisiknya yang meliputi pengamatan organoleptis, ukuran partikel, % transmisi, polydispersity index, zeta potensial, robustness to dilution serta viskositas. Kemudian dilanjutkan dengan dilakukan uji stabilitas fisik SNEDDS dengan cara sentrifugasi dan siklus heating/cooling. Berdasarkan penelitian ini didapatkan hasil bahwa perbedaan konsentrasi surfaktan dan kosurfaktan tidak berpengaruh terhadap karakteristik fisik SNEDDS yang terbentuk, serta SNEDDS yang tidak stabil akibat atenolol yang tidak larut ke dalam pembawa SNEDDS (konsentrasi surfaktan dan kosurfaktan belum cukup kuat untuk meingkatkan kelarutan atenolol).
Kata kunci: atenolol, bioavailabilitas, nanopartikel, SNEDDS
ABSTRACT-This thesis is going to discuss about how to increase the solubility and bioavailability of Atenolol by reducing the particle size of Atenolol to form a nanoparticle (SNEDDS). In this thesis, the Atenolol SNEDDS were made into three different formulas, which have the same amount of active pharmaceutical ingredient (2%) and oil (49%) although the amount of surfactant and cosurfactant were all different, which were 45:5 for formula number one, 40:10 for formula number two, and 35:15 for formula number three. Furthermore, each of the three formulas were evaluated for its physical characteristics that include organoleptic observation, particle size, percent transmission, polydispersity index, zeta potential, robustness to dilution and viscosity. Soon after, the process were continued to the physical stability testing, using centrifugation method and heating/cooling cycle. The results that obtained from this thesis are that the differences in the concentration of surfactant and co-surfactant do not influence any of the physical characteristics of the SNEDDS, and the SNEDDS that’s been formed are physically unstable because the Atenolol doesn’t fully dissolved in the SNEEDS carrier (the surfactant and co-surfactant concentration aren’t strong enough to increase the solubility of Atenolol).
Keywords: atenolol, bioavailability, nanoparticle, SNEDDS.
Downloads
References
Chow, Professor Clara, et al. 2017. Reducing the Burden of Cardiovascular Disease in Indonesia. Jakarta: The George Institue for Global Health.
Mansoor, Aijah H, Upendra Kaul. 2009. Supplement of JAPI vol. 57: Beta Blockers in Cardiovascular Medicine. India: Association of Physicians. Harvard Medical School. 2011. Beta Blockers: Cardiac Jacks of All Trades. Boston: Harvard Health Publishing.
Wander, Gurpreet Singh, Shibba Takkar Chhabra, Kaza Kaur. 2009. Supplement of JAPI vol 57: Atenolol Drug Profile. India: Association of Physicians.
Hamidi, Samin, Abolghasem Jouyban. 2015. Solubility of Atenolol in Ethanol +Mixtures at Various Temperatures. Journal of the Serbian Chemical Society.
Date, Abhijit A, Neha Desai, Rahul Dixit, Mangal Nagasenker. 2010. Self nanoemulsifying Drug Delivery Systems: Formulation Insights, Applications and Advances. Mumbai, India: Researchgate.
Kuruvila, Febi S, Flowelet Mathew, S Kuppuswamy. 2017. Solid Self Nanoemulsifying Drug Delivery Systems (SNEDDS) Development, Applications, and Future Perspective: A Review. Kerala: Indo-American Journal of Pharmaceutical Sciences.
Health Development Department and Cardiology Department of South Eastern Health and Social Care Trust. 2013. Cardiovascular Disease: How to Help Reduce Your Risk. Dundonald: South Eastern Health and Social Care Trust.
American Heart Association. 2017. What is Cardiovascular?. Dallas: American Heart Association.
National Heart, Lung, and Blood Intitute. 2015. Coronary Heart Disease, Also Known as Coronary Artery Disease. Bethesda: National Institue of Health.
Truelsen, Thomas, Stephen Begg, Colin Mathers. The Global Burden of Cerebrovascular Disease. World Health Organization.
Date, A.A., Nagarsenker, M.S., 2007, Design and Evaluation of Self-Nanoemulsifying Drug Delivery System (SNEDDS) for Cefpodoxime Proxetil, International Journal of Pharmaceutics 329. 2007. hal 166-172.
Wahyuningsih, I., Sugiyanto, Yuswanto, A., Martien, R., 2015, Uji Kelarutan untuk Seleksi Fase Minyak, Surfaktan dan Kosurfaktan dalam Preparasi Self-Nanoemulsifying Drug Delivery System (SNEDDS) Furosemid, Fakultas Farmasi Universitas Wahid Hasyim, 99-104.
Choudhary, M., Saurabh, S.S., Pareek, A., Rathore, K.S., 2017, Self Emulsifying Drug Delivery Sytem: A Novel Drug Delivery System, International Journal of Applied Pharmaceutical and Biological Research, 2017, 2(3): 76-83.
Gupta, S., Chavhan, S., Sawant, K.K., 2011, Self Nanoemulsifying Drug Delivery System for Adefovir Dipivoxil: Design, Characterization, In Vitro and Ex Vevo Evaluation, Elsevier, 145-155.
Rowe, R.C., Sheskey, P.J., dan Quinn, M.E., 2009,Handbook of Pharmaceutical Excipients, 6th Edition, Pharmaceutical Press, London, UK.
Patel, J., Patel, A., Raval, M., Sheth, N., 2011, Formulation and Development of A Self-Nanoemulsifying Drug Delivery System of Irbesartan, Journal of Advanced Pharmaceutical Technology and Research, vol 2: 9-16.
Zadeh, Sharif Makhmal, Torabi SH, Azarpanah A. Optimization of Ibuprofen Delivery through Rat Skin from Traditional and Novel Nanoemulsion Formulations. Iran J Pharm Res . 2012; 11(1):47–58.
http://edis.ifas.ufl.edu/fs282 ( Dahl et al. 2016. Health Benefits of Olive Oil and Olive Extract. Florida: University of Florida IFAS Extension. Diakses: 31 Agustus2018, pk. 22.40 WIB)
http://www.who.int/cardiovascular_diseases/en/ (Diakses: 18 Juli2018, pk. 16.39 WIB)
http://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases (cvds) (Diakses: 18 Juli2018, pk. 16.39 WIB)
https://www.nhs.uk/conditions/cardiovascular-disease/ (Diakses: 19 Juli 2018, pk.10.42 WIB)
https://www.nhs.uk/conditions/beta-blockers/ (Diakses: 19 Juli 2018, pk. 11.05 WIB)
https://www.cdc.gov/stroke/types_of_stroke.htm (Diakses: 1 Agustus 2018, pk. 11.14 WIB)
https://www.hopkinsmedicine.org/healthlibrary/conditions/nervoussystem disorders types_of_stroke_85,P00813 (Diakses: 1 Agustus 2018, pk. 11.20 WIB)
https://www.health.ny.gov/diseases/cardiovascular/stroke/types.htm (New York State Department of Health. Types of Stroke. Diakses: 1 Agustus 2018, pk. 11.22 WIB)
https://www.nhs.uk/conditions/high-blood-pressure-hypertension/ (Diakses: 2 Agustus 2018, pk. 11.15 WIB
http://www.who.int/cardiovascular_diseases/guidelines/PocketGL.ENGL SH.AFR-DE.rev1.pdf (Diakses: 2 Agustus 2018, pk. 11.30 WIB.
- Articles published in CALYPTRA are licensed under a Creative Commons Attribution-ShareAlike 4.0 International license. You are free to copy, transform, or redistribute articles for any lawful purpose in any medium, provided you give appropriate credit to the original author(s) and the journal, link to the license, indicate if changes were made, and redistribute any derivative work under the same license.
- Copyright on articles is retained by the respective author(s), without restrictions. A non-exclusive license is granted to CALYPTRA to publish the article and identify itself as its original publisher, along with the commercial right to include the article in a hardcopy issue for sale to libraries and individuals.
- By publishing in CALYPTRA, authors grant any third party the right to use their article to the extent provided by the Creative Commons Attribution-ShareAlike 4.0 International license.
